



Preferred Drug List

NEW DRUG REVIEW

Proprietary Name: Effient™

Common Name: Prasugrel

PDL Category: Platelet Aggregation Inhibitors

<u>Comparable Products</u>	<u>Preferred Drug List Status</u>
Plavix®	Preferred
Ticlopidine	Preferred

Summary

Indications and Usage: Indicated for the reduction of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) who are managed with percutaneous coronary intervention (PCI).¹

Mechanism of Action: Inhibits platelet activation and aggregation through the irreversible binding to platelet receptors.¹

Dosage Forms: Tablets: 5mg, 10mg

Recommended Dosage: Initiate with a single 60mg oral loading dose. Continue at 10mg once daily with or without food. Consider 5mg once daily for patients < 60kg. Patients should also take 75mg to 325mg of aspirin daily.¹

Common Adverse Drug Reactions: Hypertension, hyperlipidemia, backache, headache, epistaxis, bleeding, leukopenia, atrial fibrillation, bradyarrhythmia.¹

Contraindications: Active pathological bleeding. Prior transient ischemic attack or stroke.¹

Manufacturer: Eli Lilly and Company

Analysis: Effient™ is a new oral antiplatelet drug to be used with aspirin to reduce the rate of thrombotic cardiovascular events in patients with ACS who are managed with PCI. In the trial used to gain FDA approval, Effient™ was compared to Plavix®, in addition to aspirin, for 15 months. There was a lower incidence of the primary endpoint (cardiovascular death, non-fatal myocardial infarction (MI), or non-fatal stroke) with Effient™ versus Plavix®, 9.9% and 12.1% respectively. This was mostly due to a reduction in MI. Effient™ showed no advantage over Plavix® in the rate of stroke and no significant advantage in the rate of cardiovascular death. The trial also indicates a higher risk of major bleeding with Effient™ versus Plavix®. Preferred alternatives appear on the Preferred Drug List, which have a more favorable safety profile and are more cost effective. Therefore, it is recommended that Effient™ be added to the Preferred Drug List as a non-preferred drug.

IME Recommendation: Preferred Drug Recommended Drug
 Non-Preferred Drug Non-Recommended Drug
 Preferred Drug with Conditions

1. Effient™ [package insert]. Indianapolis, IN: Eli Lilly and Company; 2009.